Intractable epilepsy: management and therapeutic alternatives

The Lancet Neurology

Volumn 7, Issue 6, 2008, Pages 514-524

  Schuele, Stephan U ^a   Lüders, Hans O ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID DERIVATIVE; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VITAMIN D; ZONISAMIDE;

ABSENCE; ALCOHOL CONSUMPTION; ANXIETY; BACTERIAL MENINGITIS; BENIGN CHILDHOOD EPILEPSY; BONE DENSITY; CAUSAL ATTRIBUTION; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGENITAL BLOOD VESSEL MALFORMATION; DIAGNOSTIC ERROR; DIGITAL IMAGING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG TREATMENT FAILURE; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EXPERIMENTAL STUDY; FETUS CELL; FOCAL EPILEPSY; GAMMA KNIFE RADIOSURGERY; GENE THERAPY; GENERALIZED EPILEPSY; GENETIC DISORDER; GLIOMA; HEMISPHERECTOMY; HIPPOCAMPAL SCLEROSIS; HUMAN; INTRACTABLE EPILEPSY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR DEPRESSION; MEDICAL RESEARCH; METABOLIC REGULATION; MONOTHERAPY; MOOD DISORDER; MYOCLONUS SEIZURE; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SEXUAL DYSFUNCTION; SLEEP DEPRIVATION; SLEEP DISORDER; SUDDEN DEATH; SUICIDE; TEMPORAL LOBE EPILEPSY; TEMPORAL LOBECTOMY; TONIC CLONIC SEIZURE; TRAUMATIC BRAIN INJURY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; VIDEORECORDING; VIRUS ENCEPHALITIS; WAVEFORM; WEST SYNDROME;

ANTICONVULSANTS; BRAIN; CHRONIC DISEASE; COMORBIDITY; ELECTRIC STIMULATION THERAPY; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; NEUROSURGICAL PROCEDURES; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 43249119642     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70108-X     Document Type: Review

References (151)

1. Duncan J., Sander J., Sisodiya S., and Walker M. Adult epilepsy. Lancet 367 (2006) 1087-1100
2. Marson A., Jacoby A., Johnson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365 (2005) 2007-2013
3. Hauser W., Rich S., Lee J., Annegers J., and Anderson V. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 338 (1998) 429-434
4. Cockerell O., Johnson A., Sander J., and Shorvon S. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 38 (1997) 31-46
5. Sillanpaa M., and Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 129 (2006) 617-624
6. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Prognostic index for recurrence of seizures after remission of epilepsy. BMJ 306 (1993) 1374-1378
7. Sander J. The natural history of epilepsy in the era of new antiepileptic drugs and surgical treatment. Epilepsia 44 suppl 1 (2003) 17-20
8. Kwan P., and Sander J. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 75 (2004) 1376-1381
9. Shorvon S., and Luciano A. Prognosis of chronic and newly diagnosed epilepsy: revisiting temporal aspects. Curr Opin Neurol 20 (2007) 208-212
10. MacDonald B., Johnson A., Goodridge D., Cockerell O., Sander J., and Shorvon S. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 48 (2000) 833-841
11. Kwan P., and Brodie M. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
12. Berg A. Defining intractable epilepsy. Adv Neurol 97 (2006) 5-10
13. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47 (2006) 1094-1120
14. French J., Kanner A., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
15. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
16. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1016-1026
17. Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 42 suppl 3 (2001) 31-35
18. Wirrell E., Whiting S., and Farrell K. Management of intractable epilepsy in infancy and childhood. Adv Neurol 97 (2006) 463-491
19. Chadwick D., and Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 48 (2007) 1259-1263
20. Perucca E. Pharmacoresistance: how should it be defined?. CNS Drugs 10 (1998) 171-179
21. Chen J., and Wasterlain C. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 5 (2006) 246-256
22. Berg A., and Kelly M. Defining intractability: comparisons among published definitions. Epilepsia 47 (2006) 431-436
23. Mattson R., Cramer J., and Collins J. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology 47 (1996) 68-76
24. Chadwick D., and Smith D. The misdiagnosis of epilepsy. BMJ 324 (2002) 495-496
25. Gumnit R., Walczak T., and National Association of Epilepsy Centers. Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States. Epilepsia 42 (2001) 804-814
26. Brodie M., and Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 15 (2001) 1-12
27. Smith D., Defalla B., and Chadwick D. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 92 (1999) 15-23
28. Scheepers B., Clough P., and Pickles C. The misdiagnosis of epilepsy: findings of a population study. Seizure 7 (1998) 403-406
29. LaFrance Jr. W., and Benbadis S. Avoiding the costs of unrecognized psychological nonepileptic seizures. Neurology 66 (2006) 1620-1621
30. Holtkamp M., Othman J., Buchheim K., and Meierkord H. Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology 66 (2006) 1727-1729
31. Henry T., and Drury I. Non-epileptic seizures in temporal lobectomy candidates with medically refractory seizures. Neurology 48 (1997) 1374-1382
32. Bateman D. Pseudostatus epilepticus. Lancet 2 (1989) 1278-1279
33. Walczak T., Papacostas S., Williams D., Scheuer M., Lebowitz N., and Notarfrancesco A. Outcome after diagnosis of psychogenic nonepileptic seizures. Epilepsia 36 (1995) 1131-1137
34. Benbadis S., Agrawal V., and Tatum IV W. How many patients with psychogenic nonepileptic seizures also have epilepsy?. Neurology 57 (2001) 915-917
35. Zivin L., and Marsan C. Incidence and prognostic significance of "epileptiform" activity in the EEG of non-epileptic subjects. Brain 91 (1968) 751-778
36. Benbadis S. Errors in EEGs and the misdiagnosis of epilepsy: Importance, causes, consequences, and proposed remedies. Epilepsy Behav 11 (2007) 257-262
37. Semah F., Picot M., Adam C., et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. Neurology 51 (1998) 1256-1262
38. Von Oertzen J., Urbach H., Jungbluth S., et al. Standard magnetic resonance imaging is inadequate for patients with refractory focal epilepsy. J Neurol Neurosurg Psychiatry 73 (2002) 643-647
39. Reynolds E. Changing view of prognosis of epilepsy. BMJ 301 (1990) 1112-1114
40. Kale R. Bringing epilepsy out of the shadows. BMJ 315 (1997) 2-3
41. Shorvon S. The treatment of chronic epilepsy: a review of recent studies of clinical efficacy and side effects. Curr Opin Neurol 20 (2007) 159-163
42. Brodie M. Management strategies for refractory localization-related seizures. Epilepsia 42 suppl 3 (2001) 27-30
43. Callaghan B., Anand K., Hesdorffer D., Hauser W., and French J. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62 (2007) 382-389
44. Luciano A., and Shorvon S. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62 (2007) 311-313
45. Cramer J., Fisher R., Ben-Menachem E., French J., and Mattson R. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
46. Barcs G., Walker E., Elger C., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41 (2000) 1597-1607
47. Cereghino J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
48. Faught E., Ayala R., Montouris G., Leppik I., and Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57 (2001) 1774-1779
49. French J., Kugler A., Robbins J., Knapp L., and Garofalo E. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 (2003) 1631-1637
50. Liimatainen S., Raitanen J., Ylinen A., Peltola M., and Peltola J. The benefit of active drug trials is dependent on the aetiology in refractory focal epilepsy. J Neurol Neurosurg Psychiatry (2007) 10.1136/jnnp.2007.132811 published online Nov 8.
51. Stephen L., Kwan P., and Brodie M. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?. Epilepsia 42 (2001) 357-362
52. Wiebe S., Blume W., Girvin J., Eliasziw M., and Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345 (2001) 311-318
53. Engel Jr. J., Wiebe S., French J., et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Epilepsia 44 (2003) 741-751
54. Engel Jr. J., Wiebe S., French J., et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 60 (2003) 538-547
55. Trevathan E., and Gilliam F. Lost years: delayed referral for surgically treatable epilepsy. Neurology 61 (2003) 432-433
56. Rosenow F., and Luders H. Presurgical evaluation of epilepsy. Brain 124 (2001) 1683-1700
57. Duncan J. Epilepsy surgery. Clin Med 7 (2007) 137-142
58. McIntosh A., Kalnins R., Mitchell L., Fabinyi G., Briellmann R., and Berkovic S. Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence. Brain 127 (2004) 2018-2030
59. Jeha L., Najm I., Bingaman W., et al. Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy. Neurology 66 (2006) 1938-1940
60. Spencer S., and Huh L. The evaluation of surgical outcome in epilepsy. Lancet Neurol 7 (2008) 525-537
61. McKhann II G., and Howard III M. Epilepsy surgery: disease treatment and investigative opportunity. In: Asbury A., McKhann II G., McDonald W., Goadsby P., and McArthur J. (Eds). Diseases of the nervous system: clinical neuroscience and therapeutic principles (2002), Cambridge University Press, Cambridge, UK
62. Ferrier C., Alarcon G., Engelsman J., et al. Relevance of residual histologic and electrocorticographic abnormalities for surgical outcome in frontal lobe epilepsy. Epilepsia 42 (2001) 363-371
63. Mosewich R., So E., O'Brien T., et al. Factors predictive of the outcome of frontal lobe epilepsy surgery. Epilepsia 41 (2000) 843-849
64. Lee S., Lee S., Kim K., Hong K., Lee D., and Chung C. Surgical outcome and prognostic factors of cryptogenic neocortical epilepsy. Ann Neurol 58 (2005) 525-532
65. Yun C., Lee S., Lee S., Kim K., Jeong S., and Chung C. Prognostic factors in neocortical epilepsy surgery: multivariate analysis. Epilepsia 47 (2006) 574-579
66. Jeha L., Najm I., Bingaman W., Dinner D., Widdess-Walsh P., and Luders H. Surgical outcome and prognostic factors of frontal lobe epilepsy surgery. Brain 130 (2007) 574-584
67. van Veelen M., Avezaat C., Kros J., van Putten W., and Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64 (1998) 581-587
68. Baumann C., Schuknecht B., Lo Russo G., et al. Seizure outcome after resection of cavernous malformations is better when surrounding hemosiderin-stained brain also is removed. Epilepsia 47 (2006) 563-566
69. Ferrier C., Aronica E., Leijten F., et al. Electrocorticography discharge patterns in patients with a cavernous hemangioma and pharmacoresistent epilepsy. J Neurosurg 107 (2007) 495-503
70. Hammen T., Romstock J., Dorfler A., Kerling F., Buchfelder M., and Stefan H. Prediction of postoperative outcome with special respect to removal of hemosiderin fringe: a study in patients with cavernous haemangiomas associated with symptomatic epilepsy. Seizure 16 (2007) 248-253
71. Awad I., and Jabbour P. Cerebral cavernous malformations and epilepsy. Neurosurg Focus 21 (2006) e7
72. Wyllie E. Catastrophic epilepsy in infants and children: identification of surgical candidates. Epileptic Disord 1 (1999) 261-264
73. Carreno M., Kotagal P., Jimenez A.P., Mesa T., Bingaman W., and Wyllie E. Intractable epilepsy in vascular congenital hemiparesis: clinical features and surgical options. Neurology 59 (2002) 129-131
74. Gonzalez-Martinez J., Gupta A., Kotagal P., et al. Hemispherectomy for catastrophic epilepsy in infants. Epilepsia 46 (2005) 1518-1525
75. Loddenkemper T., Holland K., Stanford L., Kotagal P., Bingaman W., and Wyllie E. Developmental outcome after epilepsy surgery in infancy. Pediatrics 119 (2007) 930-935
76. Zaroff C., Morrison C., Ferraris N., Weiner H., Miles D., and Devinsky O. Developmental outcome of epilepsy surgery in tuberous sclerosis complex. Epileptic Disord 7 (2005) 321-326
77. Madhavan D., Schaffer S., Yankovsky A., et al. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia 48 (2007) 1625-1628
78. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 1 (2002) 477-482
79. FineSmith R., Zampella E., and Devinsky O. Vagal nerve stimulator: a new approach to medically refractory epilepsy. N Engl J Med 96 (1999) 37-40
80. Theodore W., and Fisher R. Brain stimulation for epilepsy. Lancet Neurol 3 (2004) 111-118
81. Handforth A., DeGiorgio C., Schachter S., et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 51 (1998) 48-55
82. Morris III G., and Mueller W. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology 53 (1999) 1731-1735
83. The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 45 (1995) 224-230
84. Van Wagenen W., and Herren R. Surgical division of commissural pathways in the corpus callosum: relation to spread of an epileptic attack. Arch Neurol Psychiatry 44 (1940) 740-759
85. Whiting S., Farrell K., and Wirrell E. Diseases and syndromes associated with intractable epilepsy. Adv Neurol 97 (2006) 443-462
86. Lux A., and Osborne J. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 45 (2004) 1416-1428
87. Schmidt D., and Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf 22 (2000) 467-477
88. You S., Lee J., and Ko T. Epilepsy surgery in a patient with Lennox-Gastaut syndrome and cortical dysplasia. Brain Dev 29 (2007) 167-170
89. Bladin P. Adult Lennox Gastaut syndrome: patients with large focal structural lesions. Clin Exp Neurol 21 (1985) 105-114
90. Quarato P., Gennaro G., Manfredi M., and Esposito V. Atypical Lennox-Gastaut syndrome successfully treated with removal of a parietal dysembryoplastic tumour. Seizure 11 (2002) 325-329
91. Pomeroy S., Holmes S., Dodge P., and Feigin R. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 323 (1990) 1651-1657
92. Annegers J., Hauser W., Beghi E., Nicolosi A., and Kurland L. The risk of unprovoked seizures after encephalitis and meningitis. Neurology 38 (1988) 1407-1410
93. Annegers J., Rocca W., and Hauser W. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc 71 (1996) 570-575
94. Hauser W., Annegers J., and Rocca W. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71 (1996) 576-586
95. Diaz-Arrastia R., Agostini M., Frol A., et al. Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults. Arch Neurol 57 (2000) 1611-1666
96. Marks D., Kim J., Spencer D., and Spencer S. Seizure localization and pathology following head injury in patients with uncontrolled epilepsy. Neurology 45 (1995) 2051-2057
97. Davies K., Hermann B., Dohan Jr. F., and Wyler A. Intractable epilepsy due to meningitis: results of surgery and pathological findings. Br J Neurosurg 10 (1996) 567-570
98. O'Brien T., Moses H., Cambier D., and Cascino G. Age of meningitis or encephalitis is independently predictive of outcome from anterior temporal lobectomy. Neurology 58 (2002) 104-109
99. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 5 (1996) 149-151
100. Sullivan J., and Dlugos D. Idiopathic generalized epilepsy. Curr Treat Options Neurol 6 (2004) 231-242
101. Guerrini R., Dravet C., Genton P., Belmonte A., Kaminska A., and Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39 (1998) 508-512
102. Crespel A., Genton P., Berramdane M., et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 65 (2005) 762-764
103. Verrotti A., Manco R., di Marco G., Chiarelli F., and Franzoni E. The treatment of juvenile myoclonic epilepsy. Expert Rev Neurother 6 (2006) 847-854
104. Panayiotopoulos C., Ferrie C., Knott C., and Robinson R. Interaction of lamotrigine with sodium valproate. Lancet 341 (1993) 445
105. Rowan A., Meijer J., de Beer-Pawlikowski N., van der Geest P., and Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 40 (1983) 797-802
106. Mula M., and Sander J. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30 (2007) 555-567
107. Hermann B., and Jones J. Intractable epilepsy and patterns of psychiatric comorbidity. Adv Neurol 97 (2006) 367-374
108. Gilliam F., Barry J., Hermann B., Meador K., Vahle V., and Kanner A. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 5 (2006) 399-405
109. Gilliam F. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol 18 (2005) 129-133
110. Christensen J., Vestergaard M., Mortensen P., Sidenius P., and Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 6 (2007) 693-698
111. Kanner A., Soto A., and Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 62 (2004) 708-713
112. Pack A., and Morrell M. Treatment of women with epilepsy. Sem Neurol 22 (2002) 289-298
113. Lossius M., Tauboll E., Mowinckel P., Morkrid L., and Gjerstad L. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy: a prospective randomized double-blind withdrawal study. Epilepsia 48 (2007) 1875-1882
114. Smaldone M., Sukkarieh T., Reda A., and Khan A. Epilepsy and erectile dysfunction: a review. Seizure 13 (2004) 453-459
115. Brodtkorb E., and Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 17 (2007) 160-165
116. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors?. Seizure 17 (2008) 181-186
117. Bazil C. Sleep and epilepsy. Semin Neurol 22 (2002) 321-327
118. Foldvary N. Sleep and epilepsy. Curr Treat Options Neurol 4 (2002) 129-135
119. Lhatoo S., and Sander J. Cause-specific mortality in epilepsy. Epilepsia 46 suppl 11 (2005) 36-39
120. Nashef L., Hindocha N., and Makoff A. Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. Epilepsia 48 (2007) 859-871
121. So N., and Sperling M. Ictal asystole and SUDEP. Neurology 69 (2007) 423-424
122. Schuele S., Bermeo A., Locatelli E., Burgess R., Dinner D., and Foldvary-Schaefer N. Video-electrographic and clinical features in patients with ictal asystole. Neurology 69 (2007) 434-441
123. Beran R., Weber S., Sungaran R., Venn N., and Hung A. Review of the legal obligations of the doctor to discuss Sudden Unexplained Death in Epilepsy (SUDEP)-a cohort controlled comparative cross-matched study in an outpatient epilepsy clinic. Seizure 13 (2004) 523-528
124. Beran R. SUDEP-to discuss or not discuss: that is the question. Lancet Neurol 5 (2006) 464-465
125. Mohanraj R., Norrie J., Stephen L., Kelly K., Hitiris N., and Brodie M. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 5 (2006) 481-487
126. Ficker D., So E., Shen W., et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 51 (1998) 1270-1274
127. Sperling M., Feldman H., Kinman J., Liporace J., and O'Connor M. Seizure control and mortality in epilepsy. Ann Neurol 46 (1999) 45-50
128. Sander J., and Bell G. Reducing mortality: an important aim of epilepsy management. J Neurol Neurosurg Psychiatry 75 (2004) 349-351
129. Perucca E., French J., and Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6 (2007) 793-804
130. Pollard J., and French J. Antiepileptic drugs in development. Lancet Neurol 5 (2006) 1064-1067
131. Rogawski M., and Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 (2004) 553-564
132. Kwan P., Sills G., and Brodie M. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 90 (2001) 21-34
133. Schmidt D., and Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
134. Stein A., Eder H., Blum D., Drachev A., and Fisher R. An automated drug delivery system for focal epilepsy. Epilepsy Res 39 (2000) 103-114
135. Nilsen K., and Cock H. Focal treatment for refractory epilepsy: hope for the future?. Brain Res Brain Res Rev 44 (2004) 141-153
136. Kwan P., and Brodie M. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 6 (2006) 397-406
137. Kerrigan J., Litt B., Fisher R., et al. Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy. Epilepsia 45 (2004) 346-354
138. Velasco F., Velasco M., Jimenez F., Velasco A., and Marquez I. Stimulation of the central median thalamic nucleus for epilepsy. Stereotact Funct Neurosurg 77 (2001) 228-232
139. Motamedi G., Lesser R., Miglioretti D., et al. Optimizing parameters for terminating cortical afterdischarges with pulse stimulation. Epilepsia 43 (2002) 836-846
140. Chkhenkeli S., Sramka M., Lortkipanidze G., et al. Electrophysiological effects and clinical results of direct brain stimulation for intractable epilepsy. Clin Neurol Neurosurg 106 (2004) 318-329
141. Kossoff E., Ritzl E., Politsky J., et al. Effect of an external responsive neurostimulator on seizures and electrographic discharges during subdural electrode monitoring. Epilepsia 45 (2004) 1560-1567
142. Morrell M. Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures?. Curr Opin Neurol 19 (2006) 164-168
143. Fountas K., Smith J., Murro A., Politsky J., Park Y., and Jenkins P. Implantation of a closed-loop stimulation in the management of medically refractory focal epilepsy: a technical note. Stereotact Funct Neurosurg 83 (2005) 153-158
144. Romanelli P., and Anschel D. Radiosurgery for epilepsy. Lancet Neurol 5 (2006) 613-620
145. Schauble B., Cascino G., Pollock B., et al. Seizure outcomes after stereotactic radiosurgery for cerebral arteriovenous malformations. Neurology 63 (2004) 683-687
146. Regis J., Rey M., Bartolomei F., et al. Gamma knife surgery in mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia 45 (2004) 504-515
147. Regis J., Bartolomei F., de Toffol B., et al. Gamma knife surgery for epilepsy related to hypothalamic hamartomas. Neurosurgery 47 (2000) 1343-1351
148. Henderson C., Filloux F., Alder S., Lyon J., and Caplin D. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol 21 (2006) 193-198
149. Neal E., Chaffe H., Schwartz R., et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 7 (2008) 500-505
150. Kossoff E., McGrogan J., Bluml R., Pillas D., Rubenstein J., and Vining E. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 47 (2006) 421-424
151. Ricotti V., and Delanty N. Use of complementary and alternative medicine in epilepsy. Curr Neurol Neurosci Rep 6 (2006) 347-353